Robert A. Dean, PhD, MD, served 21 years as a clinical research pathologist and director of diagnostics and experimental medicine at Eli Lilly and Company, and joined Acumen in 2018. He supported clinical drug development through the use of biomarkers for safety assessment and to explore target engagement, pharmacology, pathophysiology and therapeutic tailoring. His work supported numerous drug development programs for cardiovascular, endocrine, oncological, psychiatric and neurodegenerative disorders with emphasis on Alzheimer’s disease. Prior to joining Lilly, Dr. Dean served as director of chemical pathology at Indiana University School of Medicine. He completed a doctorate in toxicology/pharmacology at Indiana and medical training at Indiana University, University of Vermont and the Mayo Clinic.